Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Malignant Melanoma

  Free Subscription


Articles published in Br J Cancer

Retrieve available abstracts of 74 articles:
HTML format



Single Articles


    April 2021
  1. DHOMEN N, Mundra PA, Marais R
    Sunglasses to hide behind may also prevent melanoma of the eyes.
    Br J Cancer. 2021 Apr 6. pii: 10.1038/s41416-021-01343.
    PubMed     Abstract available


  2. WANG H, Elsheikh M, Gilmour K, Cohen V, et al
    Impact of COVID-19 pandemic on eye cancer care in United Kingdom.
    Br J Cancer. 2021;124:1357-1360.
    PubMed     Abstract available


    March 2021
  3. VAN BREESCHOTEN J, Wouters MWJM, Hilarius DL, Haanen JB, et al
    Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF(V600)-mutant advanced melanoma patients: a propensity-matched survival analysis.
    Br J Cancer. 2021 Mar 15. pii: 10.1038/s41416-021-01312.
    PubMed    


  4. YE W, Olsson-Brown A, Watson RA, Cheung VTF, et al
    Checkpoint-blocker-induced autoimmunity is associated with favourable outcome in metastatic melanoma and distinct T-cell expression profiles.
    Br J Cancer. 2021 Mar 15. pii: 10.1038/s41416-021-01310.
    PubMed     Abstract available


  5. YAO S, Janku F, Subbiah V, Stewart J, et al
    Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies.
    Br J Cancer. 2021 Mar 5. pii: 10.1038/s41416-020-01230.
    PubMed     Abstract available


    February 2021
  6. BARCLAY ME, Abel GA, Greenberg DC, Rous B, et al
    Socio-demographic variation in stage at diagnosis of breast, bladder, colon, endometrial, lung, melanoma, prostate, rectal, renal and ovarian cancer in England and its population impact.
    Br J Cancer. 2021 Feb 9. pii: 10.1038/s41416-021-01279.
    PubMed     Abstract available


    January 2021
  7. VAN BREESCHOTEN J, Wouters MWJM, Hilarius DL, Haanen JB, et al
    First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF(V600)-mutant advanced melanoma patients: a propensity-matched survival analysis.
    Br J Cancer. 2021 Jan 26. pii: 10.1038/s41416-020-01229.
    PubMed     Abstract available


    December 2020
  8. AMERATUNGA M, Brana I, Bono P, Postel-Vinay S, et al
    First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours.
    Br J Cancer. 2020;123:1730-1736.
    PubMed     Abstract available


    November 2020
  9. KUMAR PR, Moore JA, Bowles KM, Rushworth SA, et al
    Mitochondrial oxidative phosphorylation in cutaneous melanoma.
    Br J Cancer. 2020 Nov 18. pii: 10.1038/s41416-020-01159.
    PubMed     Abstract available


  10. SMITH AJ, Lambert PC, Rutherford MJ
    Understanding the impact of sex and stage differences on melanoma cancer patient survival: a SEER-based study.
    Br J Cancer. 2020 Nov 4. pii: 10.1038/s41416-020-01144.
    PubMed     Abstract available


    October 2020
  11. BHAVE P, Pallan L, Long GV, Menzies AM, et al
    Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis.
    Br J Cancer. 2020 Oct 22. pii: 10.1038/s41416-020-01121.
    PubMed     Abstract available


  12. PAMIDIMUKKALA N, Puts GS, Kathryn Leonard M, Snyder D, et al
    Nme1 and Nme2 genes exert metastasis-suppressor activities in a genetically engineered mouse model of UV-induced melanoma.
    Br J Cancer. 2020 Oct 7. pii: 10.1038/s41416-020-01096.
    PubMed     Abstract available


  13. RABBIE R, Ferguson P, Wong K, Couturier DL, et al
    The mutational landscape of melanoma brain metastases presenting as the first visceral site of recurrence.
    Br J Cancer. 2020 Oct 7. pii: 10.1038/s41416-020-01090.
    PubMed     Abstract available


    August 2020
  14. TREMBLE LF, McCabe M, Walker SP, McCarthy S, et al
    Differential association of CD68(+) and CD163(+) macrophages with macrophage enzymes, whole tumour gene expression and overall survival in advanced melanoma.
    Br J Cancer. 2020 Aug 26. pii: 10.1038/s41416-020-01037.
    PubMed     Abstract available


  15. ALMEIDA RR, Vieira RS, Castoldi A, Terra FF, et al
    Host dysbiosis negatively impacts IL-9-producing T-cell differentiation and antitumour immunity.
    Br J Cancer. 2020;123:534-541.
    PubMed     Abstract available


    July 2020
  16. MIDDLETON MR, Hoeller C, Michielin O, Robert C, et al
    Intratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectives.
    Br J Cancer. 2020 Jul 27. pii: 10.1038/s41416-020-0994.
    PubMed     Abstract available


  17. CHEUNG VTF, Gupta T, Olsson-Brown A, Subramanian S, et al
    Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?
    Br J Cancer. 2020;123:207-215.
    PubMed     Abstract available


    April 2020
  18. TROIANI T, Giunta EF, Tufano M, Vigorito V, et al
    Alternative macrophage polarisation associated with resistance to anti-PD1 blockade is possibly supported by the splicing of FKBP51 immunophilin in melanoma patients.
    Br J Cancer. 2020 Apr 22. pii: 10.1038/s41416-020-0840.
    PubMed     Abstract available


  19. MCNEILLIS R, Greystoke A, Walton J, Bacon C, et al
    A case of malignant hyperlactaemic acidosis appearing upon treatment with the mono-carboxylase transporter 1 inhibitor AZD3965.
    Br J Cancer. 2020;122:1141-1145.
    PubMed     Abstract available


    February 2020
  20. GRANADOS K, Huser L, Federico A, Sachindra S, et al
    T-type calcium channel inhibition restores sensitivity to MAPK inhibitors in de-differentiated and adaptive melanoma cells.
    Br J Cancer. 2020 Feb 17. pii: 10.1038/s41416-020-0751.
    PubMed     Abstract available


  21. SPAIN L, Larkin J, Turajlic S
    New survival standards for advanced melanoma.
    Br J Cancer. 2020 Feb 17. pii: 10.1038/s41416-020-0738.
    PubMed    


  22. AYA-BONILLA CA, Morici M, Hong X, McEvoy AC, et al
    Detection and prognostic role of heterogeneous populations of melanoma circulating tumour cells.
    Br J Cancer. 2020 Feb 10. pii: 10.1038/s41416-020-0750.
    PubMed     Abstract available


    January 2020
  23. TIAGO M, Capparelli C, Erkes DA, Purwin TJ, et al
    Targeting BRD/BET proteins inhibits adaptive kinome upregulation and enhances the effects of BRAF/MEK inhibitors in melanoma.
    Br J Cancer. 2020 Jan 14. pii: 10.1038/s41416-019-0724.
    PubMed     Abstract available


    December 2019
  24. ICE RJ, Chen M, Sidorov M, Le Ho T, et al
    Drug responses are conserved across patient-derived xenograft models of melanoma leading to identification of novel drug combination therapies.
    Br J Cancer. 2019 Dec 20. pii: 10.1038/s41416-019-0696.
    PubMed     Abstract available


  25. GUPTA A, Towers C, Willenbrock F, Brant R, et al
    Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma.
    Br J Cancer. 2019 Dec 16. pii: 10.1038/s41416-019-0673.
    PubMed     Abstract available


  26. DELGADO-GONI T, Galobart TC, Wantuch S, Normantaite D, et al
    Increased inflammatory lipid metabolism and anaplerotic mitochondrial activation follow acquired resistance to vemurafenib in BRAF-mutant melanoma cells.
    Br J Cancer. 2019 Dec 10. pii: 10.1038/s41416-019-0628.
    PubMed     Abstract available


    July 2019
  27. CHESNEY J, Puzanov I, Collichio F, Milhem MM, et al
    Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma.
    Br J Cancer. 2019 Jul 29. pii: 10.1038/s41416-019-0530.
    PubMed     Abstract available


    March 2019
  28. SANTOS IP, Caspers PJ, van Doorn R, Koljenovic S, et al
    Reply to Comment on "Improving clinical diagnosis of early-stage cutaneous melanoma based on Raman spectroscopy".
    Br J Cancer. 2019 Mar 22. pii: 10.1038/s41416-019-0431.
    PubMed    


  29. DE GIORGI V, Scarfi F, Gori A, Topa A, et al
    Comment on "Improving clinical diagnosis of early-stage cutaneous melanoma based on Raman spectroscopy".
    Br J Cancer. 2019 Mar 22. pii: 10.1038/s41416-019-0430.
    PubMed    


    February 2019
  30. DONLEY GM, Liu WT, Pfeiffer RM, McDonald EC, et al
    Reproductive factors, exogenous hormone use and incidence of melanoma among women in the United States.
    Br J Cancer. 2019 Feb 28. pii: 10.1038/s41416-019-0411.
    PubMed     Abstract available


  31. LIU C, He H, Li X, Su MA, et al
    Dynamic metrics-based biomarkers to predict responders to anti-PD-1 immunotherapy.
    Br J Cancer. 2019;120:346-355.
    PubMed     Abstract available


    November 2018
  32. P SANTOS I, van Doorn R, Caspers PJ, Bakker Schut TC, et al
    Improving clinical diagnosis of early-stage cutaneous melanoma based on Raman spectroscopy.
    Br J Cancer. 2018 Nov 9. pii: 10.1038/s41416-018-0257.
    PubMed     Abstract available


    September 2018
  33. HAMID O, Robert C, Ribas A, Hodi FS, et al
    Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006.
    Br J Cancer. 2018 Sep 11. pii: 10.1038/s41416-018-0207.
    PubMed     Abstract available


    August 2018
  34. SILVA IPD, Batten M, Long GV
    Reinvigorating tumour-infiltrating lymphocytes from checkpoint inhibitor resistant melanomas.
    Br J Cancer. 2018 Aug 21. pii: 10.1038/s41416-018-0218.
    PubMed    


  35. KRISP C, Parker R, Pascovici D, Hayward NK, et al
    Proteomic phenotyping of metastatic melanoma reveals putative signatures of MEK inhibitor response and prognosis.
    Br J Cancer. 2018 Aug 17. pii: 10.1038/s41416-018-0227.
    PubMed     Abstract available


    July 2018
  36. LIPPLAA A, Fernandes R, Marshall A, Lorigan P, et al
    25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial.
    Br J Cancer. 2018 Jul 23. pii: 10.1038/s41416-018-0179.
    PubMed     Abstract available


  37. DUPUIS F, Lamant L, Gerard E, Torossian N, et al
    Clinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy.
    Br J Cancer. 2018 Jul 5. pii: 10.1038/s41416-018-0168.
    PubMed     Abstract available


    June 2018
  38. WAGNER NB, Forschner A, Leiter U, Garbe C, et al
    S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies.
    Br J Cancer. 2018 Jun 28. pii: 10.1038/s41416-018-0167.
    PubMed     Abstract available


  39. TIBES R, Borad MJ, Dutcus CE, Reyderman L, et al
    Safety, pharmacokinetics, and preliminary efficacy of E6201 in patients with advanced solid tumours, including melanoma: results of a phase 1 study.
    Br J Cancer. 2018 Jun 5. pii: 10.1038/s41416-018-0099.
    PubMed     Abstract available


    May 2018
  40. ADLER NR, Wolfe R, McArthur GA, Kelly JW, et al
    Tumour mutation status and melanoma recurrence following a negative sentinel lymph node biopsy.
    Br J Cancer. 2018 May 14. pii: 10.1038/s41416-018-0088.
    PubMed     Abstract available


    March 2018
  41. SCHOLZ SL, Cosgarea I, Susskind D, Murali R, et al
    NF1 mutations in conjunctival melanoma.
    Br J Cancer. 2018 Mar 21. pii: 10.1038/s41416-018-0046.
    PubMed     Abstract available


  42. DEL RE M, Marconcini R, Pasquini G, Rofi E, et al
    PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC.
    Br J Cancer. 2018 Mar 6. pii: bjc20189. doi: 10.1038/bjc.2018.
    PubMed     Abstract available


    February 2018
  43. DRENO B, Ascierto PA, Atkinson V, Liszkay G, et al
    Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAF(V600) mutation-positive melanoma.
    Br J Cancer. 2018 Feb 13. pii: bjc2017488. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  44. HECHT M, Meier F, Zimmer L, Polat B, et al
    Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients.
    Br J Cancer. 2018 Feb 13. pii: bjc2017489. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    January 2018
  45. VAN LAAR R, Lincoln M, Van Laar B
    Development and validation of a plasma-based melanoma biomarker suitable for clinical use.
    Br J Cancer. 2018 Jan 23. pii: bjc2017477. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  46. LI WQ, Drucker AM, Cho E, Laden F, et al
    Tetracycline use and risk of incident skin cancer: a prospective study.
    Br J Cancer. 2018;118:294-298.
    PubMed     Abstract available


    December 2017
  47. WU CE, Esfandiari A, Ho YH, Wang N, et al
    Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma.
    Br J Cancer. 2017 Dec 12. pii: bjc2017433. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    November 2017
  48. HUGDAHL E, Kalvenes MB, Mannelqvist M, Ladstein RG, et al
    Prognostic impact and concordance of TERT promoter mutation and protein expression in matched primary and metastatic cutaneous melanoma.
    Br J Cancer. 2017 Nov 9. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  49. ZUGNA D, Senetta R, Osella-Abate S, Fierro MT, et al
    Favourable prognostic role of histological regression in stage III positive sentinel lymph node melanoma patients.
    Br J Cancer. 2017 Nov 9. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    October 2017
  50. POYNTER JN, Richardson M, Roesler M, Krailo M, et al
    Family history of cancer in children and adolescents with germ cell tumours: a report from the Children's Oncology Group.
    Br J Cancer. 2017 Oct 24. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    September 2017
  51. CIRILLO N, Morgan DJ, Pedicillo MC, Celentano A, et al
    Characterisation of the cancer-associated glucocorticoid system: key role of 11beta-hydroxysteroid dehydrogenase type 2.
    Br J Cancer. 2017;117:984-993.
    PubMed     Abstract available


    August 2017
  52. ADLER NR, Wolfe R, Kelly JW, Haydon A, et al
    Tumour mutation status and sites of metastasis in patients with cutaneous melanoma.
    Br J Cancer. 2017 Aug 8. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  53. KUZU OF, Gowda R, Noory MA, Robertson GP, et al
    Modulating cancer cell survival by targeting intracellular cholesterol transport.
    Br J Cancer. 2017;117:513-524.
    PubMed     Abstract available


    July 2017
  54. BOIA-FERREIRA M, Basilio AB, Hamasaki AE, Matsubara FH, et al
    TCTP as a therapeutic target in melanoma treatment.
    Br J Cancer. 2017 Jul 27. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  55. WASTER P, Orfanidis K, Eriksson I, Rosdahl I, et al
    UV radiation promotes melanoma dissemination mediated by the sequential reaction axis of cathepsins-TGF-beta1-FAP-alpha.
    Br J Cancer. 2017 Jul 11. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    May 2017
  56. PARAKH S, Park JJ, Mendis S, Rai R, et al
    Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases.
    Br J Cancer. 2017;116.
    PubMed     Abstract available


  57. AMIT M, Tam S, Abdelmeguid AS, Roberts DB, et al
    Mutation status among patients with sinonasal mucosal melanoma and its impact on survival.
    Br J Cancer. 2017 May 11. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    April 2017
  58. NOSRATI A, Tsai KK, Goldinger SM, Tumeh P, et al
    Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy.
    Br J Cancer. 2017;116:1141-1147.
    PubMed     Abstract available


    March 2017
  59. BOWYER S, Prithviraj P, Lorigan P, Larkin J, et al
    Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''.
    Br J Cancer. 2017 Mar 21. doi: 10.1038/bjc.2017.
    PubMed    


  60. IMAFUKU K, Yoshino K, Yamaguchi K, Tsuboi S, et al
    Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy'.
    Br J Cancer. 2017 Mar 21. doi: 10.1038/bjc.2017.
    PubMed    


  61. RUSHTON L, Hutchings SJ
    Reply to 'Comment on 'The burden of occupationally-related cutaneous malignant melanoma in Britain due to solar radiation'' - outdoor occupation may not be linked to increased risk of melanoma in Britain.
    Br J Cancer. 2017 Mar 16. doi: 10.1038/bjc.2017.
    PubMed    


  62. GRANT WB
    Comment on 'The burden of occupationally-related cutaneous malignant melanoma in Britain due to solar radiation'.
    Br J Cancer. 2017 Mar 16. doi: 10.1038/bjc.2017.
    PubMed    


  63. MALAPELLE U, Mayo de-Las-Casas C, Rocco D, Garzon M, et al
    Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients.
    Br J Cancer. 2017;116:802-810.
    PubMed     Abstract available


  64. KINSLER VA, O'Hare P, Jacques T, Hargrave D, et al
    MEK inhibition appears to improve symptom control in primary NRAS-driven CNS melanoma in children.
    Br J Cancer. 2017 Mar 2. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    January 2017
  65. DAUD A, Kluger HM, Kurzrock R, Schimmoller F, et al
    Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma.
    Br J Cancer. 2017 Jan 19. doi: 10.1038/bjc.2016.
    PubMed     Abstract available


  66. RUSHTON L, Hutchings SJ
    The burden of occupationally-related cutaneous malignant melanoma in Britain due to solar radiation.
    Br J Cancer. 2017 Jan 17. doi: 10.1038/bjc.2016.
    PubMed     Abstract available


  67. DALY LE, Power DG, O'Reilly A, Donnellan P, et al
    The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma.
    Br J Cancer. 2017 Jan 10. doi: 10.1038/bjc.2016.
    PubMed     Abstract available


    November 2016
  68. HUBNER J, Waldmann A, Geller AC, Weinstock MA, et al
    Interval cancers after skin cancer screening: incidence, tumour characteristics and risk factors for cutaneous melanoma.
    Br J Cancer. 2016 Nov 29. doi: 10.1038/bjc.2016.
    PubMed     Abstract available


  69. LI X, Liang L, Feng YA, De Vivo I, et al
    Height, height-related SNPs, and risk of non-melanoma skin cancer.
    Br J Cancer. 2016 Nov 15. doi: 10.1038/bjc.2016.
    PubMed     Abstract available


    October 2016
  70. KAUR A, Webster MR, Weeraratna AT
    In the Wnt-er of life: Wnt signalling in melanoma and ageing.
    Br J Cancer. 2016 Oct 20. doi: 10.1038/bjc.2016.
    PubMed     Abstract available


  71. CARLINO MS, Vanella V, Girgis C, Giannarelli D, et al
    Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series.
    Br J Cancer. 2016 Oct 6. doi: 10.1038/bjc.2016.
    PubMed     Abstract available


  72. GUPTA A, Roberts C, Tysoe F, Goff M, et al
    RADVAN: a randomised phase 2 trial of WBRT plus vandetanib for melanoma brain metastases - results and lessons learnt.
    Br J Cancer. 2016 Oct 6. doi: 10.1038/bjc.2016.
    PubMed     Abstract available


  73. KHOJA L, Kibiro M, Metser U, Gedye C, et al
    Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients.
    Br J Cancer. 2016 Oct 4. doi: 10.1038/bjc.2016.
    PubMed     Abstract available


    September 2016
  74. TITTARELLI A, Guerrero I, Tempio F, Gleisner MA, et al
    Overexpression of connexin 43 reduces melanoma proliferative and metastatic capacity.
    Br J Cancer. 2016 Sep 22. doi: 10.1038/bjc.2016.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: